Navigation Links
Gene variants may predict who will benefit from breast cancer prevention drugs
Date:6/13/2013

going breast cancer preventive treatment take tamoxifen or raloxifene for five years. In rare cases, the drugs can cause dangerous side effects, including blood clots, strokes and endometrial cancer.

Many women never try the therapy because the chance of success seems small (about 50 women in the NSABP trials needed to be treated to prevent one case of breast cancer) compared to the perceived risk of side effects. More women might benefit from the potentially life-saving strategy if doctors could better predict whether the therapy was highly likely to work. That's what the current study begins to do.

The investigators leveraged data from past NSABP breast cancer prevention trials that involved a total of more than 33,000 high-risk womenthe largest sets of such data in the world. Women in the trials gave scientists permission to use their genomic and other information for research purposes.

The scientists analyzed the genomic data by focusing on more than 500,000 genetic markers called single nucleotide polymorphisms (SNPs). Each SNP represents a single variation in the DNA sequence at a particular location within the genome.

To determine whether any SNPs were associated with breast cancer risk, the researchers computationally searched for SNPs that occurred more commonly in women who developed breast cancer during the trial than in women who remained free of the disease. The analysis identified two such SNPsone in a gene called ZNF423 and the other near a gene called CTSO.

Neither ZNF423 nor CTSOnor any SNPs related to these geneshad previously been associated with breast cancer or response to the preventive drugs. The scientists' work revealed that women with the beneficial version of the two SNPs were 5.71 times less likely to develop breast cancer while taking preventive drugs than were women with neither advantageous SNP.

Using a variety of biochemical studies, the scientists learned that ZNF423 and CTSO ac
'/>"/>

Contact: Alisa Z Machalek
alisa.machalek@nih.gov
301-496-7301
NIH/National Institute of General Medical Sciences
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Common genetic variants identify autism risk in high risk siblings of children with ASD
2. Study examines effects of genetic variants for infants with neonatal abstinence syndrome
3. Disease-carrying colonizers on the move: Predicting the spread of ticks across Canada
4. Supplement use predicts folate status in Canadian women
5. Researchers identified a protein useful in predicting the risk of pulmonary metastases in breast cancer patients
6. University of Toronto biologists predict extinction for organisms with poor quality genes
7. Scientists develop new technique that could improve heart attack prediction
8. Striatal brain volume predicts Huntington disease onset
9. Discovery of mechanisms predicting response to new treatments in colon cancer
10. Tufts Medical Center researchers finds marker in premies saliva predicts readiness to feed by mouth
11. Researchers identify genetic markers to predict male fertility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/3/2014)... Research and Markets has announced the addition of ... Companies" to their offering. This report ... already started to play an important role in the practice ... fashioned bone marrow transplants. Role of cells in drug discovery ... part of medical practice. Stem cells are discussed ...
(Date:11/3/2014)...  NeuroSigma ® , Inc. (NeuroSigma), a ... on commercialization of its non-invasive Monarch ... neurological and neuropsychiatric disorders, announced today that the ... Notice of Allowance for Mexican Patent Application No. ... and the Regents of the University of California ...
(Date:11/2/2014)... Physics World , James Dacey explores the ways in ... take their innovations from the lab into the commercial ... all start-up companies as they move from prototype to ... main factors: physics-based inventions are usually far from market-ready ... be a lot more complicated than had been originally ...
Breaking Biology News(10 mins):Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3The 'valley of death' facing physics start-ups 2
... back Cedric Humes was able to play against Boston ... in part, to a prototype composite brace designed for ... professor of materials science and engineering in the College ... Goforth, Virginia Tech's director of athletic training shortly after ...
... More women choosing C-sections when no medical necessity exists ... rates;Nevada, Washington, Florida increase most , The number ... section (C-section) rose by 36.6 percent from 2001 to ... the leading provider of independent healthcare ratings. The study ...
... Kirkwood of the University of Newcastle, there is no single ... get food, produce offspring and survive danger - not to ... body slowly breaks down. , This topic was of great ... genomics and disease" taking place in Oslo, Norway. Thomas ...
Cached Biology News:Virginia Tech football player uses prototype cast 2'Patient-choice' C-section rate rises 36%: HealthGrades study 2'Patient-choice' C-section rate rises 36%: HealthGrades study 3
(Date:11/26/2014)... YORK , Nov. 26, 2014 The ... may indicate the company is looking to expand in ... further sales.  The healthcare market research firm says that  ... to Kalorama Information,s biennial survey of the IVD market ... and any change in its composition would likely affect ...
(Date:11/26/2014)... 2014 On January, 14, 2015, ... Washington D.C. science community to the UMBC campus for ... by the Protein Society, will take place from 9 ... 312. Through discussion, presentations and workshops, the free ... proteins, their role in the industry and the future ...
(Date:11/26/2014)... Whitehouse Laboratories is pleased to ... County (New Jersey) Chamber of Commerce as a ... organization in the North Jersey area, offers Whitehouse ... key clients in the pharmaceutical and biotechnology areas ... Membership enables Whitehouse Laboratories a higher level of ...
(Date:11/26/2014)... ADDISON, TX (PRWEB) November 25, 2014 ... age-defying skincare products, earned three prestigious MarCom Awards for ... , Nerium received a Platinum MarCom Award, the organization’s ... Real Event in St. Louis held in April of ... for more than 14,000 attendees. Additionally, Nerium was awarded ...
Breaking Biology Technology:Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 3Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2
... Calif., Feb. 14 Onyx,Pharmaceuticals, Inc. (Nasdaq: ONXX ... management to discuss fourth quarter and full year 2007,financial ... 19,2008, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific ... December 31, 2007 will be released,earlier that day., ...
... for Open DICOM Standard DR and Data Management Systems Spurs ... Forty-Five Percent Growth for ... Systems, a,leading developer of digital radiography (DR), PACS (Picture Archiving ... announced the company,s revenues grew 45 percent,to surpass $35 million ...
... Developing and ... SOLANA BEACH, Calif., Feb. 14 ZyGEM Corp. Ltd., ... and detection and other life sciences applications, today,announced the appointment ... Clinical Advisory Board. Dr. Ahn and the new advisory board ...
Cached Biology Technology:Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results Teleconference and Webcast 2Eklin Medical Reports Record Revenues for 2007 2Eklin Medical Reports Record Revenues for 2007 3ZyGEM Appoints Leading Biotechnology Expert to Head Clinical Advisory Board 2ZyGEM Appoints Leading Biotechnology Expert to Head Clinical Advisory Board 3
... effect inhibition assays, also known as CPE and ... supernatents; serum from PK studies and delivery formulations. ... as the quantity of interferon required per milliliter ... by 50%. All standards used in ...
Request Info...
...
... Purity is >95%\nNEN Radiolabeled Ligands\n\nReceptor-related research has ... of new radiolabeled ligands selected to keep ... wide range of products and services for ... 400 state-of-the-art radioligands. If you do not ...
Biology Products: